Background: This study details the long-term management of severe case of canine atopic dermatitis (CAD) in an eight-year-old male Beagle dog with a three-year history of recurrent pruritus responsive to corticosteroids. Diagnosis was based on clinical presentation, fulfillment of all eight Favrot&rsquo;s criteria and exclusion of other differentials. 
 
Methods: Lokivetmab was administered subcutaneously at 2 mg/kg every 30 days over 12 months following a test dose with no adverse effects. Disease severity was assessed at 30-day intervals using CADESI-04, Pruritus Visual Analogue Scale (PVAS), Erythema Severity Score (ESS), dermatoscopic erythema index (EIRGB) and hemato-biochemical analysis. 
 
Result: Pruritus resolved within the first 30 days but re-emerged thereafter, necessitating monthly dosing. CADESI-04 scores decreased from 91 at baseline to 59 by Day 120 and remained stable through Day 360. There was a drastic reduction in erythema with partial or complete lesion resolution in most sites. PVAS scores declined by &ge;50% and ESS reduced from 3 to 1. Dermatoscopy supported these findings. Hematological and biochemical parameters remained within normal limits throughout.

Long Term Use of Lokivetmab Monotherapy and its Expression in a Beagle with Severe Atopic Dermatitis: First Clinical Study from India